UPDATE : Tuesday, March 19, 2019
상단여백
Dementia drug Exelon’s insurance coverage expanded for Parkinson’s disease
Novartis Korea’s dementia treatment Exelon (rivastigmine) obtained expanded...
by Kim Yun-mi  |  2019-02-01 17:02
라인
‘Alunbrig works better for ALK-positive non-small cell lung cancer’
Second-line treatment options are increasing for patients with anaplastic l...
by Kim Yun-mi  |  2019-02-01 15:38
라인
Medytox, Daewoong continue to squabble over BTX
A heated debate is continuing between Medytox and Daewoong Pharmaceuticals ...
by Lee Han-soo  |  2019-02-01 15:36
라인
Santen Pharma to sell Huonland’s eye drop in China
Huonland said Wednesday that it has signed a memorandum of understanding wi...
by Lee Han-soo  |  2019-02-01 11:56
라인
14 pharmaceuticals to release gastritis generic drugs soon
Fourteen pharmaceutical firms are to roll out generic copies of Stillen 2X ...
by Lee Hye-seon  |  2019-02-01 11:55
라인
AbClon transfers target antibody technology to GC Labcell
GC Labcell said Wednesday that it has signed a 3 billion won ($2.7 million)...
by Lee Han-soo  |  2019-01-31 16:23
라인
Novo Nordisk’s growth hormone injection gets expanded coverage
Novo Nordisk said Wednesday that the Ministry of Health and Welfare would e...
by Lee Han-soo  |  2019-01-31 15:18
라인
‘Pseudoephedrine-containing drugs could cause acute skin reaction’ 
The government is likely to add a warning in the instructions of pseudoephe...
by Lee Hye-seon  |  2019-01-31 14:34
라인
Kwangdong dismisses rumors of terminating sales for Contrav
Kwangdong Pharmaceutical denied Thursday rumors of the company stopping sal...
by Lee Han-soo  |  2019-01-31 14:32
라인
Ipsen’s renal cancer drug Carbometyx gets insurance benefit
Ipsen Korea’s advanced renal cell carcinoma treatment Carbometyx (cabozanti...
by Park Gi-taek  |  2019-01-31 11:13
라인
₩4.7 billion spent on compensation for side effect injuries in 4 years
Korea used 4.74 billion won ($4.24 million) to compensate the damages such ...
by Lee Hye-seon  |  2019-01-30 17:18
라인
Pfizer’s lung cancer drug Xalkori threatened by new rivals
Pfizer’s Xalkori (ingredient: crizotinib) has been solidifying its status a...
by Kim Yun-mi  |  2019-01-30 12:34
라인
Biogen, NHIS begin price talk for spinal muscular atrophy treatment
The National Health Insurance Service (NHIS) and Biogen started price negot...
by Lee Han-soo  |  2019-01-30 11:43
라인
GC to stop making 1st thrombolytic agent amid poor sales
GC will stop manufacturing Urokinase, Korea’s first thrombolytic agent, aft...
by Lee Han-soo  |  2019-01-29 16:44
라인
Sanofi gets nod to increase dosage for multiple sclerosis treatment
Sanofi Genzyme Korea said that the Ministry of Food and Drug safety has exp...
by Lee Han-soo  |  2019-01-28 17:02
라인
BMS withdraws Opdivo application for TMB high lung cancer in US
Bristol-Myers Squibb (BMS) said Thursday that it had voluntarily pulled its...
by Lee Han-soo  |  2019-01-28 15:25
라인
ISU Abxis confirms safety profile for immunotherapy candidate
ISU Abxis has published an interim report confirming the safety profile for...
by Lee Han-soo  |  2019-01-28 14:34
라인
4 local firms win exclusive rights to sell Pradaxa’s generic copies
The Supreme Court recently ruled that drugmakers’ alteration of an original...
by Lee Hye-seon  |  2019-01-28 11:56
라인
Humedix to supply osteoarthritis treatment to Huons, Shin Poong
Humedix said Thursday that it has signed an agreement to supply, sell and l...
by Lee Han-soo  |  2019-01-24 18:11
라인
US sales of J&J’s Remicade sink due to biosimilars’ challenge
The U.S. sales of Johnson & Johnson's (J&J) Remicade, a blockbuster ant...
by Lee Han-soo  |  2019-01-24 11:44
여백
여백
여백
Back to Top